The Antibiotic Revolution: The Technology That Made Industrial Confinement Possible
What it is
The discovery of penicillin by Alexander Fleming in 1928, and its mass production beginning in 1944, is usually understood as a medical story — the birth of the age of antibiotics, the defeat of bacterial infection, the saving of millions of lives. Its role in enabling the industrialization of animal agriculture is almost never mentioned in the same breath. It should be. Without antibiotics, factory farming as we know it would be impossible.
History & domestication
The connection between antibiotics and animal production was discovered almost accidentally. In 1948, Thomas Jukes and colleagues at American Cyanamid were studying the nutritional effects of aureomycin (chlortetracycline) in poultry. They observed that chickens fed trace amounts of the antibiotic as a byproduct of the drug's fermentation grew faster and larger than control birds. The antibiotic appeared to function as a growth promoter at sub-therapeutic doses — doses too low to treat infection but sufficient to produce measurable production advantages. The mechanism was not fully understood then and remains partially debated now, but appears to involve changes to the gut microbiome, reduced energy expenditure on immune response, and improved feed conversion.
The implications for the poultry industry were immediately grasped. By the early 1950s, antibiotic growth promoters were in widespread use. Regulatory barriers were low: the FDA approved the use of antibiotics in animal feed with minimal scrutiny, in an era when the development of antibiotic resistance was understood as a theoretical rather than imminent problem. The use spread from poultry to swine, to cattle, to virtually all industrial livestock production. What made this particularly consequential for the story of factory farming was the second function of sub-therapeutic antibiotics: disease suppression in conditions of confinement.
Before antibiotics, the density at which animals could be kept was constrained by disease dynamics. Pack chickens too tightly and respiratory disease — Newcastle disease, infectious bronchitis, Marek's disease — would sweep through the flock. Keep pigs in close confinement without adequate ventilation and manure management, and respiratory pathogens would devastate production. The land itself seemed to set limits: animals kept too long on the same ground would accumulate parasitic loads that stunted their growth and killed them. The land needed to rest; the animals needed to move.
Antibiotics dissolved this constraint. With sub-therapeutic doses of antibiotics in the feed and water, animals could be kept at densities that would otherwise trigger epidemic disease. The biology was overridden by chemistry. A technology developed to save human lives in hospital wards was repurposed to make possible the confinement of 100,000 chickens in a single shed.
By the early 2000s, approximately 80% of all antibiotics sold in the United States were being administered to livestock — not to treat sick animals, but prophylactically, to prevent the diseases that high-density confinement would otherwise cause, and to promote growth. This figure, derived from FDA sales data, represents one of the most significant and least publicly understood facts about the American food system. The implications for antibiotic resistance — the evolution of bacterial strains that no longer respond to drugs that once killed them — have been a subject of escalating alarm in the public health community for decades.
The antibiotic resistance crisis is not a future threat; it is a present reality. The World Health Organization has identified antimicrobial resistance as one of the greatest threats to global health. Drug-resistant strains of Salmonella, Campylobacter, E. coli, and Staph aureus — many with clear links to livestock production environments — are responsible for increasingly difficult-to-treat infections in human medicine. The pipeline of new antibiotic development has slowed dramatically; the bacteria are evolving faster than the drugs. Epidemiologists have documented the flow of resistant bacteria from feedlots and poultry CAFOs through manure application, surface water runoff, and direct contact with farm workers into the broader environment and human population.
The regulatory response has been slow and contested. In 2017, the FDA issued Guidance for Industry 213, which removed growth promotion as an approved use for antibiotics important to human medicine and required veterinary oversight for their use in animal feed — a significant but incomplete step, since prophylactic use for disease prevention in confinement conditions remained permitted. The European Union moved earlier and more comprehensively, banning antibiotic growth promoters in animal feed in 2006, with a more stringent 2022 regulation restricting prophylactic use as well. The results in European poultry and swine production have been instructive: antibiotic use dropped significantly, animal mortality increased modestly in the short term, and producers adapted through improved hygiene, ventilation, and management — in other words, by partially reversing the conditions that necessitated the antibiotics in the first place.
Ecological role
The flow of antibiotics through the food animal system and into the environment is a global ecological event. Antibiotics excreted in manure reach soil and waterways, where they kill susceptible bacteria and select for resistant strains. The resistome — the collective pool of antibiotic resistance genes in the environment — has expanded dramatically in the antibiotic era, particularly near intensive livestock operations. This has implications not just for human medicine but for the microbial ecology of agricultural soil, where antibiotics can disrupt the nitrogen-cycling bacteria on which soil fertility depends.
Ethical dimensions
The use of antibiotics in factory farming raises two distinct ethical questions. The first is the question of antibiotic resistance: does any industry have the right to degrade a shared medical resource — the effectiveness of antibiotics — for its own production advantage? The commons framing is important here. Antibiotic effectiveness is a shared human good; its erosion through agricultural misuse imposes costs on every person who will ever need antibiotics to treat a serious infection. The second question is more direct: the sub-therapeutic use of antibiotics is primarily about making high-density confinement possible. If the only way to keep 100,000 chickens in a single building without mass disease is to medicate them continuously, does that tell us something important about whether 100,000 chickens should be in a single building?
Reference notes
Cross-link to: Antibiotic Resistance and Food Safety, CAFOs (Concentrated Animal Feeding Operations), Industrial Poultry Production, The Broiler Chicken, Antibiotic-Free and Organic Meat Labeling.
---